Bavarian Nordic CFO: 15-20% of RSV market would be "very attractive"
Danish vaccine maker Bavarian Nordic will probably not be the first to get a product onto the RSV market, but it isn’t looking to conquer the entire field – the CFO would be happy with less.
by christian bundgaard, translated by catherine brett
Bavarian Nordic is not short of competitors on the market for an RSV vaccine, as Pfizer, Moderna and GSK are also chasing the lucrative indication.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
GSK's RSV vaccine candidate wins FDA priority review status
For subscribers
Bavarian Nordic's Q3 revenue exceeds DKK 1bn
For subscribers
